WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

2024 is on track to be a pivotal year for evidence in support of using the Signatera molecular residual disease (MRD) assay as a patient selection and early efficacy marker in drug development.

Signatera data was shown in >20 presentations and posters at ASCO 2024. Signatera is also backed by >60 peer reviewed publications and has been tested across >150,000 real-world patients and >500,000 longitudinal timepoints to-date.

Our expert speakers will discuss the latest data from ASCO and recent conferences and publications and opportunities to escalate treatment for high-risk populations across tumor types and treatment settings.

Highlights of data to be covered include, but are not limited to:

Breast cancer: In a cohort of 940 patients enrolled in the MonarchE study, ctDNA+ in the adjuvant setting was highly prognostic of clinical outcomes (Loi et al, ASCO 2024)
- Multi-institutional analysis of real-world testing showed ctDNA-positivity impacted the care plan of 91% patients analyzed (Lipsyc-Sharf et al., ASCO 2024)
Gastroesophageal cancer: ctDNA results in the peri-operative setting correlated with long-term outcomes; persistently positive Signatera results were associated with inferior RFS, OS and/or pathological response.
Bladder cancer: Patients who remained MRD-negative on serial testing have exceptional outcomes (98% OS and 88% DFS at 18 months) and may be spared from adjuvant treatment (Powles et al., European Association of Urology 2024)
Head & Neck Cancer: Patients identified as MRD-positive Signatera after treatment had inferior PFS (Hanna et al., ASCO 2024)
Colorectal cancer: Results from the MD Anderson INTERCEPT program showed that treatment with TAS-102 was effective in inducing ctDNA clearance and prolonging DFS in patients who are MRD+ in surveillance (Pellatt et al., ASCO 2024)
- Topline results are expected to read out later this year from the randomized Phase III ALTAIR trial studying the impact of treatment with TAS-102 in an MRD+ population.

watch now

Adham Jurdi

Oncology Medical Director, Natera

Adham Jurdi, MD, is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr Jurdi practiced at Austin Cancer Center, SUNY Upstate Medical University and the Syracuse VAMC. Throughout his clinical career, he was involved in GI oncology and precision medicine research.

Angel Rodriguez

Oncology Medical Director, Natera

Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was the principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

Michael Krainock

Oncology Associate Medical Director, Natera

Michael Krainock, MD, PhD, is a Medical Director in Thoracic Oncology at Natera. Michael is a physician-scientist by training with experience in biotechnology and life sciences innovation. After completing his medical degree at the University of Nevada, Michael went on to earn a PhD at the University of Southern California, studying the epigenetic regulation of epithelial-to-mesenchymal transformation. Michael completed residency training in general surgery at Loma Linda University Medical Center and fellowship training in cardiothoracic surgery at the University of Pittsburgh Medical Center. Michael has also received an MBA from the Gies College of Business - University of Illinois.

Adam ElNaggar

ONCOLOGY MEDICAL DIRECTOR, NATERA

Dr. Adam ElNaggar joined Natera in 2021 as the Medical Director for genitourinary and gynecologic cancers. Prior to this, he was at West Cancer Center and Research Institute where he served as Director of Gynecologic Cancer Research, Associate Fellowship Director, and on the National Comprehensive Cancer Network (NCCN) ovarian cancer panel. Dr. ElNaggar earned his medical degree at Indiana University School of Medicine and completed his residency in obstetrics and gynecology at the University of Tennessee Health Science Center in Memphis, TN. He then completed his fellowship in gynecologic oncology at The Ohio State University Comprehensive Cancer Center.

moderator

John Simmons

Global VP Biopharma, Natera

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.